Education
About Us
Working with TipRanks
Follow Us
Nurix Therapeutics (NRIX)
NASDAQ:NRIX
Total Valuation
Nurix Therapeutics has a market cap or net worth of $750.38M. The enterprise value is $413.71M.
Market Cap$750.38M
Enterprise Value$413.71M
Share Statistics
Nurix Therapeutics has 76,883,440 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding76,883,440
Owned by Insiders4.87%
Owned by Institutions0.30%
Financial Efficiency
Nurix Therapeutics’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -36.69%.
Return on Equity (ROE)-0.37
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-36.69%
Return on Capital Employed (ROCE)-0.37
Revenue Per Employee190.73K
Profits Per Employee-676.81K
Employee Count286
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nurix Therapeutics is ―. Nurix Therapeutics’s PEG ratio is -0.88.
PE Ratio―
PS Ratio27.21
PB Ratio2.82
Price to Fair Value2.82
Price to FCF-8.16
Price to Operating Cash Flow-3.57
PEG Ratio-0.88
Income Statement
In the last 12 months, Nurix Therapeutics had revenue of 54.55M and earned -193.57M in profits. Earnings per share was -2.88.
Revenue54.55M
Gross Profit38.12M
Operating Income-213.03M
Pretax Income-193.30M
Net Income-193.57M
EBITDA-196.60M
Earnings Per Share (EPS)-2.88
Cash Flow
In the last 12 months, operating cash flow was -230.38M and capital expenditures -10.98M, giving a free cash flow of -241.36M billion.
Operating Cash Flow-230.38M
Free Cash Flow-241.36M
Free Cash Flow per Share-3.14
Dividends & Yields
Nurix Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.15
52-Week Price Change-61.37%
50-Day Moving Average9.54
200-Day Moving Average12.61
Relative Strength Index (RSI)52.45
Average Volume (3m)1.17M
Important Dates
Nurix Therapeutics upcoming earnings date is Feb 18, 2026, After Close (Confirmed).
Last Earnings DateOct 9, 2025
Next Earnings DateFeb 18, 2026
Ex-Dividend Date―
Financial Position
Nurix Therapeutics as a current ratio of 6.46, with Debt / Equity ratio of 15.17%
Current Ratio6.46
Quick Ratio6.46
Debt to Market Cap0.00
Net Debt to EBITDA0.42
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Nurix Therapeutics has paid 270.00K in taxes.
Income Tax270.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Nurix Therapeutics EV to EBITDA ratio is -7.13, with an EV/FCF ratio of -7.71.
EV to Sales25.71
EV to EBITDA-7.13
EV to Free Cash Flow-7.71
EV to Operating Cash Flow-8.13
Balance Sheet
Nurix Therapeutics has $428.83M in cash and marketable securities with $56.49M in debt, giving a net cash position of $372.34M billion.
Cash & Marketable Securities$428.83M
Total Debt$56.49M
Net Cash$372.34M
Net Cash Per Share$4.84
Tangible Book Value Per Share$7.85
Margins
Gross margin is 94.03%, with operating margin of -390.52%, and net profit margin of -354.85%.
Gross Margin94.03%
Operating Margin-390.52%
Pretax Margin-354.36%
Net Profit Margin-354.85%
EBITDA Margin-360.41%
EBIT Margin-390.52%
Analyst Forecast
The average price target for Nurix Therapeutics is $26.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$26.67
Price Target Upside173.26% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast48.32%
EPS Growth Forecast-1.91%